Cancer Biomarkers Market Innovations: Advancements in Liquid Biopsy Technologies

 The global cancer biomarkers market size is expected to reach a value of USD 69.76 billion by 2030 and is anticipated to expand at a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.

 

In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.

 

People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.

 

 

Access the Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Prostate Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, By Technology, By Region, And Segment Forecasts, 2024 - 2030

 

 

Cancer Biomarkers Market Report Highlights

·        The breast cancer segment held a significant market share in terms of revenue in 2023 and it is also expected to be the witness the fastest CAGR over the forecast period.

 

·        The others segment held a notable share in 2023 pertaining to the increased research on rare cancers, advancements in genomics and proteomics, the rising incidence of cancers such as pancreatic and ovarian, and the growing demand for personalized medicine.

 

·        The genetic biomarkers segment dominated the market in terms of revenue share in 2023. Genetic biomarkers are crucial in the cancer biomarkers market due to several driving factors.

 

·        The epigenetics segment is expected to be the fastest growing segment over the forecast period. One of the key drivers boosting the growth of the segment is the growing research for the development of novel biomarkers.

 

·        The diagnostics segment dominated the market in terms of revenue share in 2023. Factors such as the growing development of cancer biomarkers based on oncology tests that are highly efficient and effective and growing government initiatives may drive the segment's growth.

 

·        The personalized medicine segment is the fastest growing segment during the forecast period.

 

·        The imaging technologies segment dominated the market share in 2023 due to its high-throughput nature, accuracy, and broad applicability in biomarker discovery and diagnosis.

 

·        North America dominated the cancer biomarkers market with revenue share of 43.84% in 2023. This dominance is due to the presence of numerous market players dedicated to cancer biomarkers and substantial investments by the U.S. government in research and development efforts, which foster innovation.

 

·        Asia Pacific cancer biomarkers market is anticipated to witness the fastest growth at a CAGR of 14.3% over the forecast period.

 

 

Order your free sample copy of “Cancer Biomarkers Market Report 2024 - 2030, published by Grand View Research

 

 

Key Cancer Biomarkers Company Insights

Some of the key companies in the Cancer Biomarkers market include Abbott Laboratories QIAGEN;Thermo Fisher Scientific Inc;Affymetrix Inc;Illumina, Inc.;Agilent Technologies;F. Hoffmann-La Roche AG;Merck & Co. Inc;Hologic, Inc and Sino Biological Inc. Vendors in the market are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

 

Abbott offers a wide variety of assays to test for many types of cancer, including breast and colon. It also offer personalized oncology testing solutions for early detection, diagnosis, and monitoring needs.

 

QIAGEN offers services for sample collection and data interpretation, utilizing robust technologies and resources to assist in detecting, analyzing, and validating relevant biomarkers. It continues to innovate and expand its range of solutions.

 

Key Cancer Biomarkers Companies:

The following are the leading companies in the cancer biomarkers market. These companies collectively hold the largest market share and dictate industry trends.

 

·        Abbott

·        QIAGEN

·        Thermo Fisher Scientific Inc

·        Affymetrix Inc

·        Illumina, Inc.

·        Agilent Technologies

·        F. Hoffmann-La Roche AG

·        Merck & Co. Inc

·        Hologic, Inc

·        Sino Biological Inc

 

 

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email:  sales@grandviewresearch.com

Comments

Post a Comment

Popular posts from this blog

Drug Addiction - Pipeline Review, H1 2017 Market Overview and trends research report

Radiant insights, inc latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape. Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes. Report Highlights Radiant insights, inc Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, p...
Read more

All Countries Dialyzer Industry 2013-2028 - Market Size, Share, Outlook, Growth, Key Players and Forecast

The global Dialyzer market was valued at $XX million in 2018, and Radiant Insights, Inc analysts predict the global market size will reach $XX million by the end of 2028, growing at a CAGR of XX% between 2018 and 2028. This report provides detailed historical analysis of global market for Dialyzer from 2013-2018, and provides extensive market forecasts from 2019-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Dialyzer market. Download Free Sample Report @ https://www.radiantinsights.com/research/2013-2028-report-on-global-dialyzer-market/request-sample Leading players of Dialyzer including: • Fresenius Medical Care • Baxter • Nipro • Asahi Kasei • Toray • B.Braun • Nikkiso • Medtronic • Kawasumi • Medica • Wego • Lengthen • Peony Medical • Chengdu OCI • Bain Medical Equipment Market split by Type, can be divided into: • Flat Type Dialyzer • Coil Tube Dialyzer • Ho...
Read more

Insights into the Medical Waste Disposal Category: A Comprehensive Procurement Intelligence Report

  Medical Waste Disposal Category Overview The medical waste disposal category is anticipated to grow at a CAGR of 6.0% from 2023 to 2030. Appropriate disposal of medical trash is the key challenge for healthcare providers across the globe. Rising awareness about the benefits of proper medical waste management for treatment, recycling, and disposal of medical trash has boosted the growth of the category. According to the World Health Organization Study Report 2022, countries with low income generate over 0.2 kg of medical trash per day per hospital bed, whereas countries with high income generate hazardous waste of up to 0.5 kg per hospital bed each day. Moreover, rising government initiatives and strict rules and regulations for waste management are also expected to drive the category. For instance, in December 2022, an MOU was signed between the Center for Health Environment Research and Development and Can Tho Central General Hospital under USAID’s Reducing Pollution Project. T...
Read more